BiotechTube
Avobis Bio

Avobis Bio

San Diego, United States· Est.
avobisbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Avobis Bio is a private, pre-revenue biotech founded in 2020 and headquartered in San Diego, CA, USA. The company is pioneering an implantable tissue healing technology platform that integrates mesenchymal stem cells (MSCs) with bioabsorbable materials to create durable, curative therapies for immune-mediated diseases and oncology. Its lead candidate, AVB-114, is in clinical development for Crohn's perianal fistulas, a condition with significant unmet need. The company leverages strategic partnerships with Mayo Clinic and W. L. Gore & Associates and is led by a seasoned team with deep experience in regenerative medicine and product development.

Gastroenterology (Crohn's Disease)ImmunologyOncology

Technology Platform

Proprietary implantable tissue healing platform combining mesenchymal stem cells (MSCs) with bioabsorbable materials to amplify the body's natural regenerative capabilities.

Opportunities

A significant unmet need exists for curative treatments for Crohn's perianal fistulas, a debilitating condition affecting hundreds of thousands globally.
Success with AVB-114 would validate a platform technology with broad potential across multiple chronic wound and tissue repair indications in immunology and oncology.

Risk Factors

The company faces high clinical development risk as its novel, implantable cell therapy must prove safety and efficacy in a complex disease.
As a pre-revenue private company, it is dependent on raising capital, and it operates in a competitive landscape with other advanced therapies in development for fistulizing Crohn's disease.

Competitive Landscape

The competitive landscape for perianal fistulas includes immunosuppressants, antibiotics, and surgical procedures, all with high failure rates. Other biotechs are developing stem cell therapies (e.g., darvadstrocel/Cx601, approved in EU) and advanced biologics. Avobis differentiates with its specific implantable MSC-bioabsorbable matrix combination product.

More companies in United States →